Skip to main content
KOBAYASHI PHARMACEUTICAL CO.,LTD. logo

KOBAYASHI PHARMACEUTICAL CO.,LTD. — Investor Relations & Filings

Ticker · 4967 ISIN · JP3301100008 LEI · 529900WBSL04KD6TKP95 T Manufacturing
Open in API
Filings indexed 74 across all filing types
Latest filing 2021-11-11 Interim / Quarterly Rep…
Country JP Japan
Listing T 4967

About KOBAYASHI PHARMACEUTICAL CO.,LTD.

https://www.kobayashi.co.jp/english/

Kobayashi Pharmaceutical Co., Ltd. is a company engaged in the development, manufacturing, and marketing of a wide range of consumer products. Its core business segments include over-the-counter (OTC) pharmaceuticals, health and personal care items, and household goods. The company's diverse product portfolio features items such as nutritional supplements, deodorizing air fresheners, and disposable body warmers. Kobayashi Pharmaceutical focuses on creating innovative and niche products designed to solve specific, everyday problems for consumers, reflecting its brand slogan, 'You make a wish and we make it happen'.

Recent filings

Filing Released Lang Actions
四半期報告書－第104期第3四半期(令和3年7月1日－令和3年9月30日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Kobayashi Pharmaceutical Co., Ltd., covering the third quarter of the 104th fiscal period (July 1, 2021, to September 30, 2021). It contains detailed financial statements, including the balance sheet, income statement, and comprehensive income statement, as well as management analysis. It is a formal regulatory filing submitted to the Kinki Finance Bureau under the Financial Instruments and Exchange Act. This fits the definition of an Interim/Quarterly Report (IR). 9M 2021
2021-11-11 Japanese
四半期報告書－第104期第2四半期(令和3年4月1日－令和3年6月30日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Kobayashi Pharmaceutical Co., Ltd., covering the second quarter of the 104th fiscal period (April 1, 2021, to June 30, 2021). It contains detailed financial statements, management analysis, and audit review information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2021
2021-08-06 Japanese
四半期報告書－第104期第1四半期(令和3年1月1日－令和3年3月31日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Kobayashi Pharmaceutical Co., Ltd. for the first quarter of the 104th fiscal period (January 1, 2021, to March 31, 2021). It contains detailed financial statements, including the balance sheet and income statement, and management analysis. It is a formal regulatory filing submitted to the Kinki Finance Bureau under the Financial Instruments and Exchange Act. Therefore, it is classified as an Interim/Quarterly Report (IR). Q1 2021
2021-05-13 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act, signed by the CEO and CFO of Kobayashi Pharmaceutical. It serves as an officer certification confirming the accuracy of the company's Annual Securities Report (Yuuka Shouken Houkokusho). According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type. FY 2020
2021-03-26 Japanese
内部統制報告書－第103期(令和2年1月1日－令和2年12月31日)
Governance Information Classification · 100% confidence The document is an 'Internal Control Report' (内部統制報告書) filed under the Financial Instruments and Exchange Act of Japan. It details the company's framework, scope, and evaluation results regarding internal controls over financial reporting. Since this is a specific regulatory filing required by law and does not fit into the other categories like 10-K (Annual Report) or ER (Earnings Release), it is classified as a Regulatory Filing.
2021-03-26 Japanese
有価証券報告書－第103期(令和2年1月1日－令和2年12月31日)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K annual report. It explicitly states '有価証券報告書' (Securities Report) as the document type, cites the Financial Instruments and Exchange Act Article 24, Paragraph 1, and covers a full fiscal year (第103期, 2020-01-01 to 2020-12-31). It contains extensive XBRL tagging and financial data, confirming it is the full annual report rather than an announcement. FY 2020
2021-03-26 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.